Starpharma Ret. on assets
What is the Ret. on assets of Starpharma?
The Ret. on assets of Starpharma Holdings Limited is -20.25%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Health Care sector on ASX compared to Starpharma
What does Starpharma do?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Companies with ret. on assets similar to Starpharma
- Great Thunder Gold has Ret. on assets of -20.32%
- Sienna Cancer Diagnostics has Ret. on assets of -20.32%
- Nutanix has Ret. on assets of -20.30%
- Insight Select Income Fund has Ret. on assets of -20.28%
- Mayne Pharma has Ret. on assets of -20.28%
- Zhidao International () has Ret. on assets of -20.26%
- Starpharma has Ret. on assets of -20.25%
- Thunderstruck Resources has Ret. on assets of -20.24%
- Mako Mining has Ret. on assets of -20.22%
- Whitewater Acquisition has Ret. on assets of -20.21%
- Namibia Critical Metals has Ret. on assets of -20.21%
- Trimantium GrowthOps has Ret. on assets of -20.21%
- Futong Technology Development has Ret. on assets of -20.20%